Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1997-10-22
|
pubmed:abstractText |
Hepatocellular carcinoma (HCC), a chemoresistant tumour, is the most common fatal cancer in Taiwan. Hepatocellular carcinoma frequently expresses a high level of P-glycoprotein (P-gp), which is a specific phenotype of a multidrug-resistance gene, and harbours mutations of the tumour suppressor gene p53. A modulatory relationship between p53 and P-gp has been reported. In this study, we analysed the expression of P-gp in relation to chemotherapeutic response and p5353 protein expression in advanced HCC. Prechemotherapeutic tumour samples were obtained from 25 patients with HCC which had been treated with either etoposide (VP-16) or doxorubicin. P-glycoprotein and p53 in HCC were visualized by immunohistochemical staining using the monoclonal antibodies JSB-1 and DO1, respectively. We investigated the correlation of P-gp expression with chemotherapeutic responses, clinicopathological features and p53 protein expression. In our study, seven cases achieved partial remission, and the remaining 18 cases had a poor response to chemotherapy. Expression of P-gp was observed in 13 tumours (52%). Positive P-gp protein expression was significantly associated with non-responders (8% or 1/13 vs 50% or 6/12, P = 0.03). Thus, P-gp expression inversely correlated with chemotherapeutic response. Expression of p53 protein was seen in 12 cases and did not correlate with chemosensitivity or P-gp expression. In summary, P-gp expression correlates with the chemosensitivity of HCC that has been treated with VP-16 or doxorubicin and p 53 mutations do not appear to be a major determinant of P-gp expression in advanced HCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0815-9319
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
569-75
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9304508-Adult,
pubmed-meshheading:9304508-Aged,
pubmed-meshheading:9304508-Antineoplastic Agents,
pubmed-meshheading:9304508-Carcinoma, Hepatocellular,
pubmed-meshheading:9304508-Doxorubicin,
pubmed-meshheading:9304508-Etoposide,
pubmed-meshheading:9304508-Female,
pubmed-meshheading:9304508-Humans,
pubmed-meshheading:9304508-Immunohistochemistry,
pubmed-meshheading:9304508-Liver Neoplasms,
pubmed-meshheading:9304508-Male,
pubmed-meshheading:9304508-Middle Aged,
pubmed-meshheading:9304508-P-Glycoprotein,
pubmed-meshheading:9304508-Tumor Suppressor Protein p53
|
pubmed:year |
1997
|
pubmed:articleTitle |
Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation.
|
pubmed:affiliation |
Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
|
pubmed:publicationType |
Journal Article
|